Hospira Inc (HSP) 33.92 0.115

Hospira, Inc.
(HSP) 33.92 0.115

Last Trade:	33.905	Day Range:	33.82 - 34.53
Trade Time:	11:02AM	52wk Range:	26.92 - 59.20
Prev. Close:	33.79	Market Cap:	5.58B
Open:	34.01	Div Yield:	0
Volume:	723623	PE:	220
EPS:	1.55

The Latest On HSP

Notable Put Options Activity in Hospira 1/19/12 1:36pm

Bank of America Adds Hospira to US 1 List 1/17/12 7:18am

ETF Showdown: Fun With Pharma 12/30/11 4:10pm

Notable Call Options Activity in Hospira 12/30/11 11:45am

UBS Initiated Hospira at Sell, $25 PT 12/15/11 11:10am

Top 4 Stocks In The Drug Delivery Industry With The Highest EPS 12/13/11 4:10am

Hospira Board Announces Retirement of Executive Chairman and Former CEO Christopher B. Begley 12/7/11 4:32pm

Morgan Stanley Has Equal-weight on Hospira 11/29/11 1:32pm

Gabelli Has Buy on Hospira 11/17/11 9:00am

Notable Put Options Activity in Hospira 11/2/11 12:03pm

Disclosure Insight Maintains Medium Risk Rating on Hospira 11/1/11 5:51am

Notable Put Options Activity in Hospira 10/28/11 11:28am

Notable Put Options Activity in Hospira 1/19/12

Bank of America Adds Hospira to US 1 List 1/17/12

ETF Showdown: Fun With Pharma 12/30/11

Notable Call Options Activity in Hospira 12/30/11

UBS Initiated Hospira at Sell, $25 PT 12/15/11

Top 4 Stocks In The Drug Delivery Industry With The Highest EPS 12/13/11

Hospira Board Announces Retirement of Executive Chairman and Former CEO Christopher B. Begley 12/7/11

Morgan Stanley Has Equal-weight on Hospira 11/29/11

Gabelli Has Buy on Hospira 11/17/11

Notable Put Options Activity in Hospira 11/2/11

Disclosure Insight Maintains Medium Risk Rating on Hospira 11/1/11

Notable Put Options Activity in Hospira 10/28/11

ETF Showdown: Fun With Pharma 12/30/11

Top 4 Stocks In The Drug Delivery Industry With The Highest EPS 12/13/11

Morgan Stanley Has Equal-weight on Hospira 11/29/11

Financial Breakfast: Morning News Summary for October 27, 2011 10/27/11

Allergan Earnings Preview: Analysts Expect Higher EPS, Revenue 10/25/11

Stocks to Watch for Wednesday 8/03/2011: Fresh 52 Week Highs and Lows 8/3/11

Earnings Preview: Allergan's EPS, Revenue Expected to Rise 7/29/11

Wednesday's S&P 500 Sector Recap: Hottest and Coldest Sectors 7/27/11

Top 4 Stocks In The Drug Delivery Industry With The Highest Operating Margin 6/9/11

Top 4 NYSE Stocks In The Drug Delivery Industry With The Highest Revenue (HSP, VRX, ELN, KV-A) 4/7/11

Top 4 Stocks In The Drug Delivery Industry With The Highest Cash (HSP, ELN, NKTR, ALKS) 11/2/10

Top 4 Stocks In The Drug Delivery Industry With The Highest Cash (ELN, HSP, NKTR, ALKS) 10/14/10

Bank of America Adds Hospira to US 1 List 1/17/12

UBS Initiated Hospira at Sell, $25 PT 12/15/11

Morgan Stanley Has Equal-weight on Hospira 11/29/11

Gabelli Has Buy on Hospira 11/17/11

Disclosure Insight Maintains Medium Risk Rating on Hospira 11/1/11

Benzinga's Top Upgrades 10/27/11

Bank of America Upgrades Hospira from Neutral to Buy 10/27/11

Hearing Hospira Downgraded to Underperform at RBC Capital 10/27/11

Financial Breakfast: Morning News Summary for October 27, 2011 10/27/11

UPDATE: Citi Lowers PT on Hospira to $30 10/19/11

Citigroup Lowers PT on Hospira to $30 10/19/11

End-of-Day Market Summary for October 18, 2011 10/18/11

Trade HSP
NOW!

Partner Headlines

Weekly Guru Bargains Highlights: SOHU, NFG, CHK, HSP, PT 2/10/12

Edward Owens' Vanguard Health Care Fund Biggest Buys in Fourth Quarter 1/30/12

Gilead, Celgene Join Big Pharma On M&A Front 1/27/12

Momenta Plunges As Lovenox Fight Tilts Toward Watson 1/26/12

Medicines Co. Settles with APP - Analyst Blog 1/24/12

Biotechs Cut Biosimilar Deals As FDA Carves Path 1/20/12

UBS: 8 Pharma Stocks to Watch 1/20/12

Biosimilars: The Next Big Thing - Analyst Blog 1/13/12

Ariel Funds Top Buys: "We think like Halvorsen: CRL is a buy" 1/11/12

Ognar Seeks Underappreciated, Fast-Growing Companies 1/4/12

Analysts' Actions: AEO, NFLX, ARO, YUM, PC 12/1/11

Hospira Still at Underperform - Analyst Blog 11/11/11

Press Releases

Multiband Announces Expanded Installation Fulfillment Relationship with ViaSat 2/1/12 Newswire Story

Multiband Announces Expiration of Letter of Intent to Acquire WPCS International Incorporated 1/31/12 Newswire Story

Hospira Names Richard Davies Chief Commercial Officer 1/30/12 Newswire Story

Hospira to Host Conference Call for Fourth-Quarter 2011 Results and 2012 Projections 1/16/12 Newswire Story

Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Hospira, Inc. 1/13/12 Business Wire Story

Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program 1/9/12 Newswire Story

DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial) 1/5/12 Newswire Story

CORRECTING and REPLACING Glancy Binkow & Goldberg LLP Announces That a Class Action Lawsuit Against Hospira, Inc. Has Been Filed and the Lead Plaintiff Deadline is January 20, 2012 1/4/12 Business Wire Story

Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against Hospira, Inc. 12/29/11 Business Wire Story

Multiband to Present at the Sidoti & Company, LLC Semi-Annual New York Micro-Cap Conference 12/29/11 Newswire Story

Harwood Feffer LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Hospira Inc. 12/27/11 Business Wire Story

Glancy Binkow & Goldberg LLP Announces That a Class Action Lawsuit Against Hospira, Inc. Has Been Filed and the Lead Plaintiff Deadline is February 12, 2012 12/23/11 Business Wire Story

Get the latest HSP stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Hospira, Inc. stock price.

Hospira, Inc. by YCharts

Hospira Inc (HSP) 33.92 0.115

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On HSP

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social